Gilead Licenses Rights for HIV-1 Treatment BIC

Gilead Sciences has licensed manufacturing rights for its human immunodeficiency virus type 1 (HIV-1) treatment bictegravir (BIC) to the Medicines Patent Pool (MPP), which can sublicense those rights to generic drug makers in India, China, and South Africa for distribution in 116 low- and middle-income countries.Within those countries, Gilead added, it has expanded its licensing agreements with Sun Pharmaceutical Industries, Strides Shasun, Mylan Laboratories, and SeQuent Scientific to include B